Leerink Partnrs Brokers Increase Earnings Estimates for AXSM

Axsome Therapeutics, Inc. (NASDAQ:AXSM) – Investment analysts at Leerink Partnrs increased their Q1 2025 earnings per share (EPS) estimates for Axsome Therapeutics in a note issued to investors on Tuesday, February 18th. Leerink Partnrs analyst M. Goodman now expects that the company will post earnings per share of ($1.31) for the quarter, up from their prior estimate of ($1.48). The consensus estimate for Axsome Therapeutics’ current full-year earnings is ($2.26) per share. Leerink Partnrs also issued estimates for Axsome Therapeutics’ Q2 2025 earnings at ($1.30) EPS, Q3 2025 earnings at ($1.12) EPS, Q4 2025 earnings at ($0.72) EPS, FY2025 earnings at ($4.45) EPS, FY2026 earnings at ($1.25) EPS and FY2027 earnings at $4.10 EPS.

Axsome Therapeutics (NASDAQ:AXSM) last posted its earnings results on Tuesday, February 18th. The company reported ($0.96) EPS for the quarter, topping the consensus estimate of ($0.97) by $0.01. Axsome Therapeutics had a negative net margin of 74.47% and a negative return on equity of 223.51%. The business had revenue of $118.77 million for the quarter, compared to the consensus estimate of $117.83 million.

AXSM has been the subject of several other reports. Truist Financial raised their target price on Axsome Therapeutics from $190.00 to $200.00 and gave the stock a “buy” rating in a research report on Wednesday. William Blair restated an “outperform” rating on shares of Axsome Therapeutics in a research report on Tuesday. Wells Fargo & Company upped their target price on Axsome Therapeutics from $140.00 to $160.00 and gave the company an “overweight” rating in a report on Wednesday, February 12th. Leerink Partners increased their target price on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an “outperform” rating in a research report on Monday, February 10th. Finally, StockNews.com upgraded shares of Axsome Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, November 20th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $155.47.

Axsome Therapeutics Price Performance

Shares of NASDAQ:AXSM opened at $129.15 on Friday. The company has a debt-to-equity ratio of 3.22, a quick ratio of 2.37 and a current ratio of 2.11. Axsome Therapeutics has a 52 week low of $64.11 and a 52 week high of $134.18. The firm has a market cap of $6.30 billion, a PE ratio of -21.56 and a beta of 1.05. The firm’s fifty day moving average is $100.34 and its 200-day moving average is $94.46.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of AXSM. Raiffeisen Bank International AG bought a new stake in shares of Axsome Therapeutics during the fourth quarter worth about $51,000. Assetmark Inc. acquired a new position in Axsome Therapeutics during the 4th quarter valued at about $52,000. R Squared Ltd bought a new stake in Axsome Therapeutics during the 4th quarter worth approximately $64,000. Aquatic Capital Management LLC purchased a new stake in shares of Axsome Therapeutics in the fourth quarter worth approximately $76,000. Finally, GF Fund Management CO. LTD. bought a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $86,000. Institutional investors and hedge funds own 81.49% of the company’s stock.

Insider Activity

In other news, CFO Nick Pizzie sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $131.07, for a total transaction of $393,210.00. Following the transaction, the chief financial officer now directly owns 42,187 shares of the company’s stock, valued at $5,529,450.09. This represents a 6.64 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Company insiders own 22.40% of the company’s stock.

About Axsome Therapeutics

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.